Valuation: Dianthus Therapeutics, Inc.

Market Cap 4.03B 3.58B 3.32B 3.02B 5.7B 383B 5.8B 39.93B 15.66B 200B 15.13B 14.81B 637B P/E 2026 *
-18.8x
P/E 2027 * -15.3x
Enterprise Value 4.17B 3.71B 3.44B 3.13B 5.9B 396B 6B 41.33B 16.21B 207B 15.66B 15.33B 659B EV / Sales 2026 *
2,232x
EV / Sales 2027 * 2,282x
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -
1 day-2.89%
1 week+0.07%
Current month-6.38%
1 month-18.48%
3 months-21.94%
6 months-11.61%
Current year+100.02%
1 week 69.43
Extreme 69.43
84.85
1 month 69.43
Extreme 69.43
100.47
Current year 35.84
Extreme 35.84
117.88
1 year 32.22
Extreme 32.22
117.88
3 years 6.58
Extreme 6.58
117.88
5 years 6.58
Extreme 6.58
117.88
10 years 6.58
Extreme 6.58
117.88
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-10
Director of Finance/CFO 37 2023-09-10
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 58 2023-09-10
Director/Board Member 50 2023-09-10
Chairman 64 2023-09-10
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Exercice

Controller/Auditor

60,000 0.1864%
9/1/26 Exercice

Chief Technology Officer

69,372 0.2155%
8/19/26 Exercice

Director

8,334 0.0149%
Change 5-day change 1-year change 3-year change Capi.($)
-2.89%+0.07%+131.22%+545.50% 4.03B
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.78%-0.97%+54.09%+139.44% 37.64B
Weighted average by Cap. -2.20%-0.56%+45.18%+101.34%

Financials

2026 *2027 *
Net sales 1.87M 1.66M 1.54M 1.4M 2.64M 177M 2.69M 18.52M 7.26M 92.61M 7.02M 6.87M 295M 1.77M 1.58M 1.46M 1.33M 2.51M 168M 2.55M 17.58M 6.89M 87.9M 6.66M 6.52M 280M
Net income -206M -183M -170M -154M -291M -19.56B -296M -2.04B -800M -10.21B -773M -757M -32.54B -270M -240M -222M -202M -381M -25.58B -387M -2.67B -1.05B -13.35B -1.01B -990M -42.56B
Net Debt 141M 126M 116M 106M 200M 13.41B 203M 1.4B 549M 7B 530M 519M 22.31B 18.85M 16.76M 15.53M 14.13M 26.66M 1.79B 27.09M 187M 73.19M 934M 70.74M 69.24M 2.98B
Projected Income Statement - Annual - Dianthus Therapeutics, Inc.
Logo Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Employees
92
Date Price Change Volume
26-10-16 US$72.09 -3.27% 1,053,359
26-10-15 US$74.53 -0.31% 943,575
26-10-14 US$74.76 -3.63% 977,333
26-10-13 US$77.58 -4.89% 1,315,448
26-10-12 US$81.57 -0.97% 853,947
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Dianthus Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
72.09USD
Average target price
140.80USD
Spread / Average Target
+95.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dianthus Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DNTH Stock